Recent News

• 02.03.2026 - Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
• 10.29.2025 - Addex Increases Issued Share Capital to Create Treasury Shares
• 09.30.2025 - Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
• 09.26.2025 - Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
• 09.23.2025 - Addex Appoints Bank of New York Mellon as Depositary Bank
• 06.30.2025 - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Recent Filings

• 01.07.2026 - EX-99.1 EX-99.1
• 01.07.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.10.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.05.2025 - EFFECT Notice of Effectiveness
• 12.04.2025 - EX-99.1 EX-99.1
• 12.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.19.2025 - F-3 Registration statement by foreign private issuers
• 10.29.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]